Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).

Annika Kurreck,Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Florian Kaiser,Jens Uhlig,Michael Schenk,Jens Freiberg-Richter,Bettina Peuser,Claudio Denzlinger,Ullrich Graeven,Kathrin Heinrich,Swantje Held,Arndt Stahler,Annabel Helga Sophie Alig,Ivan Jelas,Jobst C. von Einem,Sebastian Stintzing,Clemens Giessen-Jung,Dominik Paul Modest

Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).

2021

3571Background: Early response parameters such as early tumor shrinkage (ETS), depth of response (DpR), and time to DpR represent exploratory endpoints that may serve as early efficacy endpoints an...

Keywords:

in patient
Bevacizumab
combination chemotherapy
Response Parameters
Colorectal cancer
Medicine
Oncology
Internal medicine
tumor shrinkage
Disease

Correction
Source
Cite
Save

References

Citations